Earnings Movers | Astera Labs Soars 32%; Centrus Gains 23%; Novavax Surges 17%; Arista Networks Jumps 16%

Tiger Newspress
Aug 06

Chipmaker Astera Labs, Inc. late Tuesday handily beat analyst estimates for the second quarter and guided higher for the current period. Astera Labs’ stock rose 32% on Wednesday.

The San Jose, Calif.-based company earned an adjusted 44 cents a share on sales of $191.9 million in the June quarter. Analysts polled by FactSet had expected earnings of 32 cents a share on sales of $172.5 million. In the year-earlier period, Astera Labs earned an adjusted 13 cents a share on sales of $76.9 million. That translates to year-over-year growth of 238% in earnings and 150% in sales.

Centrus reported second quarter earnings that significantly exceeded analyst expectations, driving shares up 23% as investors cheered the nuclear fuel company’s strong performance.

The American nuclear fuel supplier posted adjusted earnings of $1.59 per diluted share for the second quarter of 2025, handily beating the analyst consensus of $0.84 by 89%. Revenue came in at $154.5 million, surpassing the $130.18 million analysts had expected and despite being down 18% from $189 million in the same quarter last year.

Novavax rose 17% on Wednesday after the Maryland-based biotech reported better-than-expected Q2 financials and raised its 2025 revenue outlook, citing, among other things, collaborations related to its COVID shot, Nuvaxovid.

The company reported $239.2M in revenue for the quarter, with a ~42% YoY decline while exceeding the consensus by $74.2M, driven by a $175M milestone payment received from its partner Sanofi following the recent FDA approval for Nuvaxovid.

Arista Networks rose about 16% on Wednesday after the company’s forecast third-quarter revenue above Wall Street expectations, signaling resilient demand for its networking equipment amid growing footprint of data centers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10